Mereo BioPharma Group plc (MREO)
Automate Your Wheel Strategy on MREO
With Tiblio's Option Bot, you can configure your own wheel strategy including MREO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MREO
- Rev/Share 0.0031
- Book/Share 0.2913
- PB 1.3823
- Debt/Equity 0.0085
- CurrentRatio 8.7113
- ROIC -0.9631
- MktCap 64281360.0
- FreeCF/Share -0.2064
- PFCF -1.9462
- PE -1.5518
- Debt/Assets 0.0074
- DivYield 0
- ROE -0.7485
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MREO | Jefferies | Buy | Hold | -- | $0.5 | Dec. 30, 2025 |
| Initiation | MREO | JP Morgan | -- | Overweight | -- | $7 | March 27, 2025 |
| Initiation | MREO | Jefferies | -- | Buy | -- | $7 | Dec. 6, 2024 |
News
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 6, 2026.
Read More
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc (“Mereo” or “the Company”) (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 6, 2026.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both dates inclusive (the “Class Period”).
Read More
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Published: February 20, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc …
Read More
Portnoy Law Firm Announces Class Action on Behalf of Mereo BioPharma Group plc Investors
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mereo BioPharma Group plc, (“Mereo” or the "Company") (NASDAQ: MREO) investors of a class action on behalf of investors that bought securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). Mereo investors have until April 6, 2026 to file a lead plaintiff motion.
Read More
MREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options
Read More
Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO
Published: February 18, 2026 by: GlobeNewsWire
Sentiment: Neutral
Robbins LLP is Investigating Allegations that Mereo BioPharma Group plc (MREO) Misled Investors Regarding Phase 3 Orbit and Cosmic Studies for Setrusumab
Read More
NASDAQ: MREO INVESTOR ALERT: Berger Montague Advises Mereo BioPharma Group PLC (NASDAQ: MREO) Investors of an April 6, 2026 Deadline
Published: February 18, 2026 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 18, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.
Read More
ROSEN, A RANKED AND LEADING FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO
Published: February 17, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc (“Mereo” or “the Company”) (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 6, 2026.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both dates inclusive (the “Class Period”).
Read More
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) (“Mereo” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Mereo American Depositary Shares (“ADS's”) between June 5, 2023 and December 26, 2025, both dates inclusive (the "Class Period"). Investors have until April 6, 2026, to seek appointments as lead plaintiff.
Read More
Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO
Published: February 12, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Mereo BioPharma Group plc Investors
Published: February 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mereo BioPharma Group plc, (“Mereo” or the "Company") (NASDAQ: MREO) investors of a class action on behalf of investors that bought securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). Mereo investors have until April 6, 2026 to file a lead plaintiff motion.
Read More
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Published: February 11, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc ("Mereo" or …
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both dates inclusive (the “Class Period”).
Read More
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc (“Mereo” or “the Company”) (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 6, 2026.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma
Published: February 09, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group …
Read More
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO
Published: February 09, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both dates inclusive (the “Class Period”).
Read More
Berger Montague PC Investigating Claims on Behalf of Investors in Mereo BioPharma Group PLC (MREO) After Class Action Filing
Published: February 05, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Mereo BioPharma Group plc (MREO)
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”).
Read More
Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders to Contact the Firm for Information About Their Rights
Published: February 05, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. Mereo describes itself as a “biopharmaceutical company focused on the development of therapeutics for rare diseases.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ro.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Investigation of Mereo BioPharma Group plc (MREO) by Holzer & Holzer, LLC
Published: January 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) complied with federal securities laws. On December 29, 2025, Mereo announced the results from its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, revealing that, “[n]either study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” Following this news, the price of the Company's stock dropped.
Read More
About Mereo BioPharma Group plc (MREO)
- IPO Date 2019-04-24
- Website https://www.mereobiopharma.com
- Industry Biotechnology
- CEO Denise Vera Scots-Knight
- Employees 36